1
|
Popescu MC, Haddock NL, Burgener EB, Rojas-Hernandez LS, Kaber G, Hargil A, Bollyky PL, Milla CE. The Inovirus Pf4 Triggers Antiviral Responses and Disrupts the Proliferation of Airway Basal Epithelial Cells. Viruses 2024; 16:165. [PMID: 38275975 PMCID: PMC10818373 DOI: 10.3390/v16010165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Revised: 01/18/2024] [Accepted: 01/19/2024] [Indexed: 01/27/2024] Open
Abstract
BACKGROUND The inovirus Pf4 is a lysogenic bacteriophage of Pseudomonas aeruginosa (Pa). People with Cystic Fibrosis (pwCF) experience chronic airway infection with Pa and a significant proportion have high numbers of Pf4 in their airway secretions. Given the known severe damage in the airways of Pa-infected pwCF, we hypothesized a high Pf4 burden can affect airway healing and inflammatory responses. In the airway, basal epithelial cells (BCs) are a multipotent stem cell population critical to epithelium homeostasis and repair. We sought to investigate the transcriptional responses of BCs under conditions that emulate infection with Pa and exposure to high Pf4 burden. METHODS Primary BCs isolated from pwCF and wild-type (WT) donors were cultured in vitro and exposed to Pf4 or bacterial Lipopolysaccharide (LPS) followed by transcriptomic and functional assays. RESULTS We found that BCs internalized Pf4 and this elicits a strong antiviral response as well as neutrophil chemokine production. Further, we found that BCs that take up Pf4 demonstrate defective migration and proliferation. CONCLUSIONS Our findings are highly suggestive of Pf4 playing a role in the pathogenicity of Pa in the airways. These findings provide additional evidence for the ability of inoviruses to interact with mammalian cells and disrupt cell function.
Collapse
Affiliation(s)
- Medeea C. Popescu
- Department of Infectious Diseases, Stanford University, Stanford, CA 94305, USA (P.L.B.)
- Immunology Program, Stanford University, Stanford, CA 94305, USA
| | - Naomi L. Haddock
- Department of Infectious Diseases, Stanford University, Stanford, CA 94305, USA (P.L.B.)
- Immunology Program, Stanford University, Stanford, CA 94305, USA
| | - Elizabeth B. Burgener
- Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Laura S. Rojas-Hernandez
- Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Gernot Kaber
- Department of Infectious Diseases, Stanford University, Stanford, CA 94305, USA (P.L.B.)
| | - Aviv Hargil
- Department of Infectious Diseases, Stanford University, Stanford, CA 94305, USA (P.L.B.)
| | - Paul L. Bollyky
- Department of Infectious Diseases, Stanford University, Stanford, CA 94305, USA (P.L.B.)
| | - Carlos E. Milla
- Center for Excellence in Pulmonary Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
| |
Collapse
|
2
|
Dolz M, Monterrey DT, Beltrán-Nogal A, Menés-Rubio A, Keser M, González-Pérez D, de Santos PG, Viña-González J, Alcalde M. The colors of peroxygenase activity: Colorimetric high-throughput screening assays for directed evolution. Methods Enzymol 2023; 693:73-109. [PMID: 37977739 DOI: 10.1016/bs.mie.2023.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2023]
Abstract
Fungal unspecific peroxygenases (UPOs) are arising as versatile biocatalysts for C-H oxyfunctionalization reactions. In recent years, several directed evolution studies have been conducted to design improved UPO variants. An essential part of this protein engineering strategy is the design of reliable colorimetric high-throughput screening (HTS) assays for mutant library exploration. Here, we present a palette of 12 colorimetric HTS assays along with their step-by-step protocols, which have been validated for directed UPO evolution campaigns. This array of colorimetric assays will pave the way for the discovery and design of new UPO variants.
Collapse
Affiliation(s)
- Mikel Dolz
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | - Dianelis T Monterrey
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | - Alejandro Beltrán-Nogal
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | - Andrea Menés-Rubio
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | - Merve Keser
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | - David González-Pérez
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain
| | | | - Javier Viña-González
- EvoEnzyme S.L., C/ Faraday 7. Parque Científico de Madrid, Cantoblanco, Madrid, Spain
| | - Miguel Alcalde
- Department of Biocatalysis, Institute of Catalysis, CSIC, C/ Marie Curie 2, Cantoblanco, Madrid, Spain.
| |
Collapse
|
3
|
Quiroga J, Vidal S, Siel D, Caruffo M, Valdés A, Cabrera G, Lapierre L, Sáenz L. Novel Proteoliposome-Based Vaccine against E. coli: A Potential New Tool for the Control of Bovine Mastitis. Animals (Basel) 2022; 12:ani12192533. [PMID: 36230275 PMCID: PMC9558995 DOI: 10.3390/ani12192533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 09/13/2022] [Accepted: 09/18/2022] [Indexed: 11/25/2022] Open
Abstract
Simple Summary Mastitis is a highly prevalent disease in dairy cattle, affecting animal welfare and generating economic losses for the dairy industry. Control measures for coliform mastitis are limited, due to the constant exposure of the teat to bacteria and the emergence of antimicrobial-resistant bacteria, making vaccination an important strategy for control of mastitis. However, currently available vaccines show limited efficacy, which could be attributed to inactivation processes that alter the antigenic preservation of the vaccines. The aim of this study was to assess the efficacy of a novel vaccine against mastitis using proteoliposomes obtained from E. coli in a murine model of coliform mastitis. We demonstrated that the proteoliposome vaccine was safe, immunogenic and effective against an experimental model of E. coli mastitis, decreasing bacterial count and tissue damage. This proteoliposome vaccine is a potential new tool for prevention of mastitis. Abstract Escherichia coli is an important causative agent of clinical mastitis in cattle. Current available vaccines have shown limited protection. We evaluated the efficacy of a novel vaccine based on bacterial proteoliposomes derived from an E. coli field strain. Female BALB/c mice were immunized subcutaneously with two doses of the vaccine, 3 weeks apart. Between days 5 and 8 after the first inoculation, the females were mated. At 5–8 days postpartum, the mice were intramammary challenged with the same E. coli strain. Two days after bacterial infection, mice were euthanized, and the mammary glands were examined and removed to evaluate the efficacy and safety of the vaccine as well as the immune response generated by the new formulation. The vaccinated mice showed mild clinical symptoms and a lower mammary bacterial load as compared to non-vaccinated animals. The vaccination induced an increase in levels of IgG, IgG1 and IgG2a against E. coli in blood and mammary glands that showed less inflammatory infiltration and tissue damage, as compared to the control group. In summary, the vaccine based on bacterial proteoliposomes is safe, immunogenic, and effective against E. coli, constituting a new potential tool for mastitis control.
Collapse
Affiliation(s)
- John Quiroga
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
- Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5090000, Chile
| | - Sonia Vidal
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
| | - Daniela Siel
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
- Escuela de Medicina Veterinaria, Facultad de Ciencias de la Vida, Universidad Andres Bello, Santiago 8370035, Chile
| | - Mario Caruffo
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
- Escuela de Biotecnología, Facultad de Ciencias, Universidad Santo Tomás, Santiago 8370003, Chile
| | - Andrea Valdés
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
| | - Gonzalo Cabrera
- Programa de Biología Celular y Molecular, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380000, Chile
| | - Lissette Lapierre
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
- Correspondence: (L.L.); (L.S.); Tel.: +56-9229-785689 (L.S.)
| | - Leonardo Sáenz
- Faculty of Veterinary Sciences, Universidad de Chile, Santiago 8820808, Chile
- Correspondence: (L.L.); (L.S.); Tel.: +56-9229-785689 (L.S.)
| |
Collapse
|
4
|
Fletcher E, Pilizota T, Davies PR, McVey A, French CE. Characterization of the effects of n-butanol on the cell envelope of E. coli. Appl Microbiol Biotechnol 2016; 100:9653-9659. [DOI: 10.1007/s00253-016-7771-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2016] [Accepted: 08/01/2016] [Indexed: 01/08/2023]
|
5
|
Kamaladevi A, Balamurugan K. Lipopolysaccharide of Klebsiella pneumoniae attenuates immunity of Caenorhabditis elegans and evades by altering its supramolecular structure. RSC Adv 2016. [DOI: 10.1039/c5ra18206a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Given the prominence of lipopolysaccharide (LPS) in the pathogenesis of Gram-negative bacteria, investigations at the molecular level in in vivo conditions are in dire need to understand its role in provoking infection.
Collapse
Affiliation(s)
- Arumugam Kamaladevi
- Department of Biotechnology
- Science Campus
- Alagappa University
- Karaikudi 630 004
- India
| | | |
Collapse
|
6
|
Noyes A, Godavarti R, Titchener-Hooker N, Coffman J, Mukhopadhyay T. Quantitative high throughput analytics to support polysaccharide production process development. Vaccine 2014; 32:2819-28. [PMID: 24576849 DOI: 10.1016/j.vaccine.2014.02.034] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
The rapid development of purification processes for polysaccharide vaccines is constrained by a lack of analytical tools current technologies for the measurement of polysaccharide recovery and process-related impurity clearance are complex, time-consuming, and generally not amenable to high throughput process development (HTPD). HTPD is envisioned to be central to the improvement of existing polysaccharide manufacturing processes through the identification of critical process parameters that potentially impact the quality attributes of the vaccine and to the development of de novo processes for clinical candidates, across the spectrum of downstream processing. The availability of a fast and automated analytics platform will expand the scope, robustness, and evolution of Design of Experiment (DOE) studies. This paper details recent advances in improving the speed, throughput, and success of in-process analytics at the micro-scale. Two methods, based on modifications of existing procedures, are described for the rapid measurement of polysaccharide titre in microplates without the need for heating steps. A simplification of a commercial endotoxin assay is also described that features a single measurement at room temperature. These assays, along with existing assays for protein and nucleic acids are qualified for deployment in the high throughput screening of polysaccharide feedstreams. Assay accuracy, precision, robustness, interference, and ease of use are assessed and described. In combination, these assays are capable of measuring the product concentration and impurity profile of a microplate of 96 samples in less than one day. This body of work relies on the evaluation of a combination of commercially available and clinically relevant polysaccharides to ensure maximum versatility and reactivity of the final assay suite. Together, these advancements reduce overall process time by up to 30-fold and significantly reduce sample volume over current practices. The assays help build an analytical foundation to support the advent of HTPD technology for polysaccharide vaccines. It is envisaged that this will lead to an expanded use of Quality by Design (QbD) studies in vaccine process development.
Collapse
Affiliation(s)
- Aaron Noyes
- The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK; Pfizer, 1 Burtt Road, Andover, MA 01810, USA
| | | | - Nigel Titchener-Hooker
- The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK
| | | | - Tarit Mukhopadhyay
- The Advanced Centre for Biochemical Engineering, Department of Biochemical Engineering, University College London, Torrington Place, London WC1E 7JE, UK.
| |
Collapse
|
7
|
Noyes A, Boesch A, Godavarti R, Titchener-Hooker N, Coffman J, Mukhopadhyay T. High throughput quantification of capsular polysaccharides for multivalent vaccines using precipitation with a cationic surfactant. Vaccine 2013; 31:5659-65. [DOI: 10.1016/j.vaccine.2013.09.075] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2013] [Revised: 09/17/2013] [Accepted: 09/26/2013] [Indexed: 11/29/2022]
|
8
|
Periodate oxidation and its contribution to instrumental methods of micro-analysis—A review. Anal Chim Acta 2009; 652:85-127. [DOI: 10.1016/j.aca.2009.06.065] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2009] [Revised: 06/09/2009] [Accepted: 06/30/2009] [Indexed: 11/21/2022]
|
9
|
Monitoring of sorbitol in Pichia pastoris cultivation applying sequential injection analysis. Biochem Eng J 2008. [DOI: 10.1016/j.bej.2008.05.020] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
10
|
Muthana S, Yu H, Huang S, Chen X. Chemoenzymatic synthesis of size-defined polysaccharides by sialyltransferase-catalyzed block transfer of oligosaccharides. J Am Chem Soc 2007; 129:11918-9. [PMID: 17845050 DOI: 10.1021/ja075736b] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Saddam Muthana
- Department of Chemistry, University of California, One Shields Avenue, Davis, California 95616, USA
| | | | | | | |
Collapse
|
11
|
Yang HH, Madoff LC, Guttormsen HK, Liu YD, Paoletti LC. Recombinant group B streptococcus Beta C protein and a variant with the deletion of its immunoglobulin A-binding site are protective mouse maternal vaccines and effective carriers in conjugate vaccines. Infect Immun 2007; 75:3455-61. [PMID: 17470542 PMCID: PMC1932936 DOI: 10.1128/iai.00332-07] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2007] [Revised: 04/16/2007] [Accepted: 04/22/2007] [Indexed: 11/20/2022] Open
Abstract
Immunogenic vaccines against group B Streptococcus (GBS) have been created by coupling the GBS capsular polysaccharides (CPS) to carrier proteins. The GBS beta C protein (BCP) serves as an effective carrier while inducing protective immunity against BCP-expressing strains. BCP also binds human immunoglobulin A (IgA), a characteristic that may be undesirable for use in humans. Here, we examined the immunogenicity and protective efficacy of a recombinant GBS BCP (rBCP), an rBCP modified to eliminate its IgA-binding site (rBCP(DeltaIgA)), and their corresponding GBS serotype III CPS conjugates (III-rBCP and III-rBCP(DeltaIgA)). Deletion of the IgA-binding site or conjugation to CPS did not alter antigenic BCP epitopes. Recombinant proteins and conjugates elicited specific, high-titered IgG in mice. Antisera to rBCP, rBCP(DeltaIgA), III-rBCP, and III-rBCP(DeltaIgA) opsonized GBS strains A909 (Ia/BCP(+)) and H36B (Ib/BCP(+)) for killing by HL-60 cells; antiserum to III-rBCP and III-rBCP(DeltaIgA) also opsonized strain M781 (III/BCP(-)). Vaccination of female mice with either rBCP or rBCP(DeltaIgA) protected approximately 40% of their pups challenged with GBS strain A909. Pups born to III-rBCP- or III-rBCP(DeltaIgA)-vaccinated dams survived at rates of 56% and 66%, respectively. Over 90% of pups born to dams that received the type III CPS conjugates survived challenge with GBS strain M781. In summary, rBCP and rBCP(DeltaIgA) proteins and the conjugates containing them were immunogenic in mice, inducing both CPS- and protein-specific functional IgG. These results suggest that the rBCP(DeltaIgA) could be used as a carrier to augment the immunogenicity of the CPS while expanding coverage to GBS strains bearing BCP.
Collapse
MESH Headings
- Animals
- Animals, Newborn
- Animals, Outbred Strains
- Antibodies, Bacterial/blood
- Antigens, Bacterial/chemistry
- Antigens, Bacterial/genetics
- Antigens, Bacterial/immunology
- Antigens, Bacterial/metabolism
- Bacterial Capsules/immunology
- Binding Sites/genetics
- Female
- Gene Deletion
- Genetic Variation
- HL-60 Cells
- Humans
- Immunity, Maternally-Acquired
- Immunoglobulin A/metabolism
- Immunoglobulin G/blood
- Mice
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- Streptococcal Infections/immunology
- Streptococcal Infections/microbiology
- Streptococcal Infections/prevention & control
- Streptococcal Vaccines/administration & dosage
- Streptococcal Vaccines/immunology
- Streptococcus agalactiae/immunology
- Vaccines, Conjugate/administration & dosage
- Vaccines, Conjugate/immunology
Collapse
Affiliation(s)
- Hsiao-Hui Yang
- Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115, USA
| | | | | | | | | |
Collapse
|